MedTrace Logo

In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice

NCT01649492 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-07-25

No results posted yet for this study

Summary

The goal of this study is to evaluate the actual potential for in vivo pineapple juice inhibition with CYP2C9 substrates in human volunteers with use of diclofenac as a marker of CYP2C9 activity.

Conditions

  • Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

pineapple juice (Carrefour n°1) 500 ml/day 5 days

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Isabel Spriet, PharmD PhD · Pharmacy Dpt, University Hospitals Leuven

  • Hans Prenen, MD PhD · Digestive Oncology, University Hospitals Leuven

  • Vincent Vandecaveye, MD PhD · Radiology Dpt, University Hospitals Leuven

  • Pieter Annaert, PharmD PhD · Laboratory for Pharmacotechnology and Biopharmacy, Catholic University Leuven

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01649492 on ClinicalTrials.gov